Neimeth International Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Neimeth International Pharmaceuticals has a total shareholder equity of NGN1.7B and total debt of NGN4.1B, which brings its debt-to-equity ratio to 250.5%. Its total assets and total liabilities are NGN9.1B and NGN7.4B respectively.
Key information
250.5%
Debt to equity ratio
₦4.13b
Debt
Interest coverage ratio | n/a |
Cash | ₦2.12b |
Equity | ₦1.65b |
Total liabilities | ₦7.42b |
Total assets | ₦9.07b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NEIMETH's short term assets (NGN5.4B) do not cover its short term liabilities (NGN5.4B).
Long Term Liabilities: NEIMETH's short term assets (NGN5.4B) exceed its long term liabilities (NGN2.0B).
Debt to Equity History and Analysis
Debt Level: NEIMETH's net debt to equity ratio (121.9%) is considered high.
Reducing Debt: NEIMETH's debt to equity ratio has increased from 94.3% to 250.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NEIMETH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NEIMETH has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 46.6% each year.